Pulmonary Allergic Asthma
Discover how Melior’s unique phenotypic screening platforms can uncover the untapped value of your candidate therapeutic
Allergic asthma is a condition that is initiated by an immune response to a diverse array of allergens and is manifested by airway obstruction, hyper-reactivity, and lung inflammation. This asthmatic response can be mimicked in experimental animal models of asthma by sensitizing and then exposing them to an array of antigens.
Like the asthmatic response in humans, the animal asthma model of pulmonary inflammation is characterized by an extensive inflammatory response including an influx of leukocytes such as monocyte chemoattractant protein (MCP-1). This inflammatory response can be attenuated by administration of a number of known anti-inflammatory agents.
In this asthma mouse model we have initiated pulmonary inflammation using ovalbumin as the antigen and evaluated the effects of a well-known steroidal anti-inflammatory, dexamethasone, on the production of the inflammatory chemokine monocyte chemoattractant protein-1 (MCP-1)
This asthma animal model is normally configured as a 4 week or 1 month study. Test articles are typically administered in repeat fashion. Groups sizes of 6 to 10 animals are normally used depending upon the expected effect size of the test article.